References
- Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–67. doi:https://doi.org/10.1136/bjo.2005.081224.
- Azuara-Blanco A, Katz LJ. Dysfunctional filtering blebs. Surv Ophthalmol. 1998;43(2):93–126. doi:https://doi.org/10.1016/S0039-6257(98)00025-3.
- Maeda M, Kojima S, Sugiyama T, Jin D, Takai S, Oku H, Kohmoto R, Ueki M, Ikeda T. Effects of gelatin hydrogel containing anti-transforming growth factor-beta antibody in a canine filtration surgery model. Int J Mol Sci. 2017;18:5. doi:https://doi.org/10.3390/ijms18050985.
- Ran W, Zhu D, Feng Q. TGF-beta2 stimulates Tenon’s capsule fibroblast proliferation in patients with glaucoma via suppression of miR-29b expression regulated by Nrf2. Int J Clin Exp Pathol. 2015;8:4799–806.
- Bao H, Jiang K, Meng K, Liu W, Liu P, Du Y, Wang D. TGF-beta2 induces proliferation and inhibits apoptosis of human Tenon capsule fibroblast by miR-26 and its targeting of CTGF. Biomed Pharmacother. 2018;104:558–65. doi:https://doi.org/10.1016/j.biopha.2018.05.059.
- Shao T, Gao Q, Jiang R, Duan Y, Sun X, Ge J. Dynamic alteration of low-density lipoprotein receptor after exposure to transforming growth factor-beta2 in human Tenon’s capsule fibroblasts. J Ocul Pharmacol Ther. 2009;25(6):499–506. doi:https://doi.org/10.1089/jop.2009.0042.
- Li X, Zhang W, Shao T, Ma J, Huang L, Gao Q, Ge J. Upregulation of low-density lipoprotein receptor after exposure to transforming growth factor-beta2 in tenon’s capsule fibroblasts from patients with glaucoma. J Ocul Pharmacol Ther. 2012;28(2):179–85. doi:https://doi.org/10.1089/jop.2011.0074.
- Gal D, Ohashi M, MacDonald PC, Buchsbaum HJ, Simpson ER. Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. Am J Obstet Gynecol. 1981;139(8):877–85. doi:https://doi.org/10.1016/0002-9378(81)90952-2.
- Palanca-Capistrano AM, Hall J, Cantor LB, Morgan L, Hoop J, WuDunn D. Long-term outcomes of intraoperative 5-fluorouracil versus intraoperative mitomycin C in primary trabeculectomy surgery. Ophthalmology. 2009;116(2):185–90. doi:https://doi.org/10.1016/j.ophtha.2008.08.009.
- Yan ZC, Bai YJ, Tian Z, Hu HY, You XH, Lin JX, Liu SR, Zhuo YH, Luo RJ. Anti-proliferation effects of Sirolimus sustained delivery film in rabbit glaucoma filtration surgery. Mol Vis. 2011;17:2495–506.
- Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59(6):723–27. doi:https://doi.org/10.1006/exer.1994.1158.
- Shepard AR, Millar JC, Pang IH, Jacobson N, Wang WH, Clark AF. Adenoviral gene transfer of active human transforming growth factor-{beta}2 elevates intraocular pressure and reduces outflow facility in rodent eyes. Invest Ophthalmol Vis Sci. 2010;51(4):2067–76. doi:https://doi.org/10.1167/iovs.09-4567.
- Fuchshofer R, Yu AH, Welge-Lussen U, Tamm ER. Bone morphogenetic protein-7 is an antagonist of transforming growth factor-beta2 in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2007;48(2):715–26. doi:https://doi.org/10.1167/iovs.06-0226.
- Zada M, Pattamatta U, White A. Modulation of fibroblasts in conjunctival wound healing. Ophthalmology. 2018;125(2):179–92. doi:https://doi.org/10.1016/j.ophtha.2017.08.028.
- Anand N, Arora S, Clowes M. Mitomycin C augmented glaucoma surgery: evolution of filtering bleb avascularity, transconjunctival oozing, and leaks. Br J Ophthalmol. 2006;90(2):175–80. doi:https://doi.org/10.1136/bjo.2005.077800.
- Sherwood MB. A sequential, multiple-treatment, targeted approach to reduce wound healing and failure of glaucoma filtration surgery in a rabbit model (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2006;104:478–92.
- Mearza AA, Aslanides IM. Uses and complications of mitomycinl C in ophthalmology. Expert Opin Drug Saf. 2007;6(1):27–32. doi:https://doi.org/10.1517/14740338.6.1.27.
- Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood. 1978;52(6):1099–114. doi:https://doi.org/10.1182/blood.V52.6.1099.1099.
- Li H, Gray BD, Corbin I, Lebherz C, Choi H, Lund-Katz S, Wilson JM, Glickson JD, Zhou R. MR and fluorescent imaging of low-density lipoprotein receptors. Acad Radiol. 2004;11:1251–59. doi:https://doi.org/10.1016/j.acra.2004.08.007.
- Nikanjam M, Blakely EA, Bjornstad KA, Shu X, Budinger TF, Forte TM. Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm. 2007;328:86–94. doi:https://doi.org/10.1016/j.ijpharm.2006.07.046.
- Chen HY, Ge J, Guo Y, Jin CJ, Lan YQ, Lin MK. The inhibition effect of photody- namic on human Tenon capsule broblast cells. Zhonghua Yan Ke Za Zhi. 2003;39:160–62.
- Jordan JF, Diestelhorst M, Grisanti S, Krieglstein GK. Photodynamic modulation of wound healing in glaucoma ltration surgery. Br J Ophthalmol. 2003;87:870–75. doi:https://doi.org/10.1136/bjo.87.7.870.
- Yu X, Li X, Zhao G, Xiao J, Mo Z, Yin K, Jiang Z, Fu Y, Zha X, Tang C. OxLDL up-regulates Niemann-Pick type C1 expression through ERK1/2/COX-2/PPARalpha-signaling pathway in macrophages. Acta Biochim Biophys Sin (Shanghai). 2012;44(2):119–28. doi:https://doi.org/10.1093/abbs/gmr119.
- Wang YG, Yang TL. Liraglutide reduces oxidized LDL-induced oxidative stress and fatty degeneration in Raw 264.7 cells involving the AMPK/SREBP1 pathway. J Geriatr Cardiol. 2015;12(4):410–16. doi:https://doi.org/10.11909/j..1671-5411.2015.04.013.
- Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L, Lu J, Zhang XL, Liu BC. Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy. Acta Diabetol. 2015;52(6):1045–56. doi:https://doi.org/10.1007/s00592-015-0753-9.
- Ma KL, Liu J, Gao M, Wang CX, Ni J, Zhang Y, Zhang XL, Liu H, Wang YL, Liu BC. Activation of mTOR contributes to foam cell formation in the radial arteries of patients with end-stage renal disease. Clin Nephrol. 2014;81(6):396–404. doi:https://doi.org/10.5414/CN108189.
- Ruan XZ, Moorhead JF, Tao JL, Ma KL, Wheeler DC, Powis SH, Varghese Z. Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines. Arterioscler Thromb Vasc Biol. 2006;26(5):1150–55. doi:https://doi.org/10.1161/01.ATV.0000217957.93135.c2.
- Eid W, Dauner K, Courtney KC, Gagnon A, Parks RJ, Sorisky A, Zha X. mTORC1 activates SREBP-2 by suppressing cholesterol trafficking to lysosomes in mammalian cells. Proc Natl Acad Sci U S A. 2017;114(30):7999–8004. doi:https://doi.org/10.1073/pnas.1705304114.
- Cvenkel B, Kopitar AN, Ihan A. Inflammatory molecules in aqueous humour and on ocular surface and glaucoma surgery outcome. Mediators Inflamm. 2010;2010:939602. doi:https://doi.org/10.1155/2010/939602.
- Lee DF, Hung MC. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle. 2007;6(24):3011–14. doi:https://doi.org/10.4161/cc.6.24.5085.
- Song S, Abdelmohsen K, Zhang Y, Becker KG, Gorospe M, Bernier M. Impact of pyrrolidine dithiocarbamate and interleukin-6 on mammalian target of rapamycin complex 1 regulation and global protein translation. J Pharmacol Exp Ther. 2011;339(3):905–13. doi:https://doi.org/10.1124/jpet.111.185678.